The CASP7 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population in which the CASP7 gene is disrupted across a heterogeneous pool of A-549 cells. This product is generated by introducing targeted mutations via CRISPR/Cas9, resulting in a mixed population of edited alleles without clonal isolation. The polyclonal format offers a practical model for studying Casapse-7 loss-of-function while reflecting the genetic diversity that can arise in tumor cell populations. It is suitable for researchers requiring a knockout background without the need for single-cell-derived clonal lines.
A-549 cells are a widely characterized human lung adenocarcinoma epithelial cell line commonly used as an in vitro model for type II pulmonary epithelial cells. Derived from a 58-year-old Caucasian male with lung carcinoma, these adherent cells display epithelial morphology and retain key features of alveolar epithelial type II cells, such as surfactant production and multilamellar body formation. A-549 cells are a cornerstone of non-small cell lung cancer (NSCLC) research, employed in studies of drug metabolism, cytotoxicity, signal transduction, and cancer biology. Their well-documented genotype and ease of culture make them an ideal host for genetic manipulation.
CASP7 encodes caspase-7, a critical executioner caspase that operates downstream of both extrinsic and intrinsic apoptotic pathways. Following activation by initiator caspases such as CASP8 (via death receptors like Fas and TNFRSF10A/B) or CASP9 (through the APAF1/cytochrome c apoptosome), caspase-7 cleaves numerous intracellular substrates to dismantle the cell. Key targets include PARP1 (disabling DNA repair), DFFA/ICAD (releasing CAD to fragment DNA), LMNA (disrupting the nuclear lamina), and cytokeratins (leading to cytoskeletal collapse). Caspase-7 can be inhibited by XIAP and cIAP1/BIRC2, with SMAC/DIABLO antagonizing this inhibition, and it often collaborates with caspase-3 to execute apoptosis. Beyond classical apoptosis, caspase-7 participates in pyroptosis signaling and the broader caspase activation cascade.
In the A-549 NSCLC context, CASP7 knockout offers a powerful model to probe apoptosis resistance??a hallmark of lung adenocarcinoma. Loss of caspase-7 function allows investigation of how tumor cells evade apoptotic death in response to chemotherapeutics or targeted agents. Additionally, emerging evidence suggests non-apoptotic roles for caspase-7 in cellular processes such as migration, differentiation, and inflammation; this knockout model facilitates dissection of these moonlighting functions. The polyclonal nature of the knockout population may better recapitulate the heterogeneity of tumor subclones, providing a relevant platform for studying variable drug responses and resistance mechanisms in lung cancer.
Researchers can apply this CASP7 knockout A-549 polyclonal cell population in a variety of assays. Western blotting for cleaved caspase-7 and PARP provides direct evidence of apoptosis pathway disruption, while caspase-3/7 activity assays quantify enzymatic function. Flow cytometry using Annexin V/PI staining allows assessment of apoptotic rates, and MTT assays measure cell viability under drug treatment. Immunofluorescence microscopy enables visualization of substrate cleavage and cellular morphology, and RT-qPCR monitors transcriptional responses. These applications support studies in apoptosis signaling, drug-induced cell death, and caspase-7 substrate identification. For additional information or to inquire about custom configurations, please contact Ascent Research.
